Health Canada and FDA regulators will address recent policy updates at DIA's 21st Canada Annual Meeting in Ottawa on Nov. 7-8. The event will focus on regulatory, clinical, and pharmacovigilance challenges, including AI and the global supply chain. Attendees will have the opportunity to discuss policy updates with regulators and learn about implementing AI, equitable drug development, diversity in clinical trials, and nitrosamine impurities in drug products. The meeting will also feature a panel discussion on clinical trials and automation. To register, visit the DIA website.
Frequently Asked Questions (FAQ)
DIA to Address AI, Supply Chain, Equitable Drug Development at ... - Business Wire
Q: What topics will be addressed by the DIA (Drug Information Association)?
A: The DIA will address the latest regulatory requirements in the area of AI, supply chain, and equitable drug development.
Q: Where can I find the specific FAQs mentioned in the article?
A: The article does not provide the actual questions and answers. However, you can refer to the following official websites for relevant FAQs:
- The FDA website may have FAQs related to regulations or requirements in the drug development process. Visit: FDA FAQs.
- The Department of Defense (DoD) website may have information about securing supply chains. Visit: DoD Supply Chain FAQs.
- The Bill & Melinda Gates Foundation website may provide information about their work in equitable drug development. Visit: Gates Foundation FAQs.
Please note that these are general suggestions, and it is important to search specific websites and resources related to your specific interests or questions.